Gottlieb seeks new comparative approval standard for opioids
With just a week left before he departs from the FDA, Commissioner Scott Gottlieb on Thursday told the Senate Appropriations Committee that his agency is interested in Congress creating a new standard for opioid approvals whereby those seeking approval would be compared to opioids already on the market.
“For this to work, the FDA believes that there should be a premarket demonstration that a new opioid is superior to an already-approved opioid or opioid-containing drug for the same general indication. The standard should be that a new opioid or opioid-containing drug provides a significant advantage relative to an already-approved opioid or opioid-containing drug for the same general indication in terms of greater efficacy or greater safety,” he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.